Cardiff Oncology stockholders approve all proposals at 2025 annual meeting

Cardiff Oncology, Inc.

Seven director nominees elected, including CEO Mark Erlander, with between 20.4M and 21.2M votes each.
Ratification of BDO USA as independent auditor for FY2025: 36.3M for, 1.2M against.
Amendment to 2021 Equity Incentive Plan approved (16.9M for, 5.0M against); shares available increased to 12.15M.
Advisory say-on-pay vote on named executive officer compensation approved (18.9M for, 2.6M against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.